Silence Therapeutics (NASDAQ:SLN) Upgraded by Wall Street Zen to Hold Rating

Silence Therapeutics (NASDAQ:SLN) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other brokerages have also commented on SLN. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and set a $35.00 price target on shares of Silence Therapeutics in a research report on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $32.60.

Silence Therapeutics Price Performance

SLN opened at $6.58 on Friday. The company’s 50 day simple moving average is $5.76 and its two-hundred day simple moving average is $5.43. Silence Therapeutics has a 1-year low of $1.97 and a 1-year high of $17.84.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Silence Therapeutics had a negative return on equity of 56.38% and a negative net margin of 254.25%.The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $3.28 million. Equities research analysts anticipate that Silence Therapeutics will post -1.77 EPS for the current year.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds have recently bought and sold shares of SLN. Massar Capital Management LP acquired a new stake in shares of Silence Therapeutics during the second quarter worth about $115,000. Boothbay Fund Management LLC grew its stake in Silence Therapeutics by 1.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after buying an additional 2,409 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new position in Silence Therapeutics during the second quarter worth approximately $67,000. Evelyn Partners Investment Management Services Ltd increased its position in Silence Therapeutics by 481.3% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock worth $77,000 after buying an additional 11,868 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Silence Therapeutics by 134.1% in the second quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock valued at $48,000 after buying an additional 4,773 shares during the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.